• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Merus N.V. CS (NQ: MRUS )

    54.81 -1.74 (-3.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 785,568
    Open 56.54
    Bid (Size) 45.00 (50)
    Ask (Size) 59.62 (1)
    Prev. Close 56.55
    Today's Range 53.92 - 57.52
    52wk Range 19.80 - 61.61
    Shares Outstanding 46,530,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC
    From Merus N.V.
    Via GlobeNewswire
    Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer
    From Merus N.V.
    Via GlobeNewswire

    Performance

    YTD
    +91.51%
    +91.51%
    1 Month
    +1.05%
    +1.05%
    3 Month
    +35.43%
    +35.43%
    6 Month
    +72.03%
    +72.03%
    1 Year
    +102.92%
    +102.92%

    More News

    Read More
    Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Pricing of Upsized Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Merus N.V. Announces Proposed Public Offering of Common Shares
    From Merus N.V.
    Via GlobeNewswire
    Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC
    From Merus N.V.
    Via GlobeNewswire
    Crude Oil Rises 1%; Verastem Shares Slide
    Via Benzinga
    Exposures Fossil Fuels
    Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Via Benzinga
    Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
    Via Benzinga
    Nasdaq Gains 1%; Intuit Shares Plunge
    Via Benzinga
    Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
    Via Investor's Business Daily
    Deckers Outdoor Posts Upbeat Earnings, Joins Guardant Health, Ross Stores And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Via InvestorPlace
    Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA
    From Merus N.V.
    Via GlobeNewswire
    MRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC
    From Merus N.V.
    Via GlobeNewswire
    Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting
    From Merus N.V.
    Via GlobeNewswire
    Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
    From Merus N.V.
    Via GlobeNewswire
    Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
    From Merus N.V.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.